Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
ETH Zurich, Basel, Switzerland.
Neurorehabil Neural Repair. 2020 Aug;34(8):686-689. doi: 10.1177/1545968320931516. Epub 2020 Jun 7.
Spinal cord injury results in devastating neurological deficits accompanied by lifelong disability and significant economic burden. While the development of novel compounds or cell-based interventions for spinal cord injury is unquestionably worthwhile, a complementary approach examines current standards of care and the degree to which these can be optimized to benefit long-term neurological function. Numerous classes of drugs, already in use in the acute phase of spinal cord injury, are intriguing because they (1) readily cross the blood-spinal cord barrier to modulate activity in the central nervous system and (2) are administered during a window of time in which neuroprotection, and even some repair, are feasible. Here, we review a rare case of convergent lines of evidence from both preclinical and human studies to support the early administration of a class of drug (ie, gabapentinoids) to both foster motor recovery and reduce the severity of neuropathic pain.
脊髓损伤导致严重的神经功能缺损，伴随终身残疾和巨大的经济负担。虽然开发新型化合物或基于细胞的干预措施治疗脊髓损伤无疑是值得的，但另一种互补的方法是检查当前的护理标准，以及在多大程度上可以优化这些标准，以促进长期神经功能。许多类别的药物已经在脊髓损伤的急性期使用，它们很有吸引力，因为它们 (1) 很容易穿过血脊髓屏障，调节中枢神经系统的活动，以及 (2) 在神经保护甚至一些修复可行的时间窗口内给药。在这里，我们回顾了来自临床前和人体研究的两条证据线的罕见案例，以支持早期使用一类药物（即加巴喷丁类药物），以促进运动功能恢复和减轻神经病理性疼痛的严重程度。
